AI-Powered Insulin Resistance Screening

AI-Guided Clinical Actions

AI-Guided Actions at Every Stage

MetaboInsight provides clear, tiered recommendations based on each patient's risk level, powered by clinical guidelines and AI-enhanced pattern recognition.For every result, we outline:
>What to prescribe
>How to bill
>What to do next
Designed for real-world use in busy clinics - no guesswork, no searching. Just practical, evidence-based next steps.

CLINICAL NEED

Why Early Detection Matters

Over 88 million U.S adults have insulin resistance, most don't know it. Metaboinsight helps you detect it early with AI-enhanced screening panels that adapt to risk factors and clinical presentation.We offer 3 AI-precision-aligned panels:
1. Early Risk Panel:
Identifies early-stage insulin resistance, often years before elevated glucose or A1C levels appear. This allows for earlier intervention and improved long-term outcomes.
2. IR Panel for Normal A1C:
Identifies insulin resistance in people with a normal or borderline A1C. A group often missed by traditional screening. This helps uncover hidden metabolic risk early and prevent progression to diabetes or cardiovascular disease.
3. Perimenopausal IR Panel - detects hormonal-metabolic shifts in women over 35 during the hormonal transition to menopause. A time of elevated cardiometabolic risk is often overlooked by conventional screening.

THE OPPORTUNITY

A Smarter Way to Improve Outcomes and Revenue

Insurance-covered metabolic screening lets you detect hidden risk, personalize care, and boost reimbursement without extra workload.MetaboInsight makes it simple:
>Ready-to-use lab panels
>Built-in billing + CPT guidance
>Clinical follow-up tools for every result
Screen.Bill.Intervene. We handle the complexity so you can focus on care.